NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Real-life Experience in Brazil in Patients With Castration-resistant Prostate Cancer Treated With Olaparib+Abiraterone

WithdrawnN/A

Sponsor: AstraZeneca

Conditions: Prostatic Neoplasms

Countries: Brazil

PROCeed is an observational study assessing real world clinical endpoints and demographic characteristics in patients with castration-resistant prostate cancer treated with Olaparib+Abiraterone.

Eligibility overview

Sex: MALE

Age: 18 Years to 100 Years

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

1. Willing to provide written informed consent;
2. 18 years or older;
3. Documented histology or cytology of PCa, adenocarcinoma;
4. Documented as mCRPC;
5. Olaparib+abiraterone started after the activation of the research site.

Exclusion Criteria:

Patients participating in a clinical trial with investigational treatment for prostate cancer within 30 days before starting olaparib.

Locations (5)

Salvador, Estado de Bahia, Brazil
Natal, Rio Grande do Norte, Brazil
Santa Maria, Rio Grande do Sul, Brazil
São Paulo, Brazil
São Paulo, Brazil